Clinical trial
Perifosine in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia
NCT00422656 · Dana-Farber Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00422656 |
|---|---|
| Title | Perifosine in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia |
| Official title | A Phase II Study of Perifosine in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Waldenstrom's Macroglobulinemia |
| Intervention type | Drug |
| Interventions | Perifosine |
| Enrollment | 37 |
| Start date | Sep 1, 2006 |
| Primary completion | Jun 1, 2009 |
| Completion | Nov 1, 2012 |
| First posted | Jan 17, 2007 |
| Last update posted | Dec 26, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: